Analyst Ryan Langston from TD Cowen maintained a Buy rating on Elevance Health and increased the price target to $400.00 from $380.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ryan Langston’s rating is based on Elevance Health’s strategic positioning and stability within the managed care sector. He identifies the company’s earnings per share (EPS) consensus for 2026 as a solid foundation for growth, highlighting the relative stability of its business segments compared to peers. Langston has increased the 2026 EPS estimate to $27.25 and set a price target of $400, reflecting confidence in the company’s future performance.
Langston also notes that Elevance Health’s exposure to less risky segments like non-HIX commercial, Medicare Advantage, and prescription services positions it favorably against competitors. Despite challenges in certain areas, the company’s business mix and investments in Carelon are expected to provide a positive impact, reducing the likelihood of significant downward revisions in earnings projections. This combination of factors underpins his Buy rating for Elevance Health.
Langston covers the Healthcare sector, focusing on stocks such as Elevance Health, UnitedHealth, and Molina Healthcare. According to TipRanks, Langston has an average return of -11.7% and a 31.37% success rate on recommended stocks.